Nektar Therapeutics
NASDAQNKTR closed at $81.89 on Friday, down 5.3% on the week — yet the most consequential moves for the stock happened after the bell on Thursday, not during it. Q1 earnings hit on May 7 and the market was underwhelmed. Revenue and earnings both missed estimates, and the stock gave back 3.8% the following session. But Nektar's management moved quickly: on the same evening it reported…
Snapshot as of 24 Jun 2026
NKTR closed at $81.89 on Friday, down 5.3% on the week — yet the most consequential moves for the stock happened after the bell on Thursday, not during it. Q1 earnings hit on May 7 and the market was underwhelmed.…
Nektar Therapeutics heads into its May 7 first-quarter report carrying two compounding weights: a flurry of securities fraud class actions and a 10.7% weekly price decline that has tested the conviction of a Street…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NKTR — free to start on ORTEX.
Sign up for free →Open NKTR on ORTEX